Solaris Resources Appoints Mark Flaherty to Board of Directors
Solaris Resources Inc. has appointed Mark Flaherty as an independent director, effective November 17, 2026, succeeding Hans Wick.
Stocks · News reference
SELLAS Life Sciences Group, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical programs, including the Phase 3 REGAL trial and Phase 2 SLS009 study.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Solaris Resources Inc. has appointed Mark Flaherty as an independent director, effective November 17, 2026, succeeding Hans Wick.
SELLAS Life Sciences announced positive results from its Phase 3 REGAL trial showing that galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, demonstrated a statistically significant 41% reduction in risk of death in acute myeloid leukemia patients, with median overall survival of 24.0 months versus 14.7 months with standard treatment. The company plans to meet with the FDA and submit a biologics license application in the first half of 2027.
SELLAS Life Sciences announced positive Phase 3 REGAL trial results for its immunotherapeutic cancer vaccine Galinpepimut-S (GPS) in acute myeloid leukemia patients. GPS demonstrated a statistically significant 41% reduction in death risk with median overall survival of 24.0 months versus 14.7 months for best available treatment (p=0.035). The company plans to meet with the FDA and submit a Biologics License Application in the first half of 2027.
SELLAS Life Sciences has initiated an underwritten public offering of $150 million in common stock, with an additional option for underwriters to purchase more shares.
SELLAS Life Sciences reported that its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary endpoint, demonstrating a statistically significant improvement in overall survival for patients with acute myeloid leukemia.
SELLAS Life Sciences announced positive topline results from its Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia. GPS demonstrated a statistically significant 41% reduction in risk of death with median overall survival of 24.0 months versus 14.7 months for best available treatment (hazard ratio 0.59, p=0.035). The company plans to meet with the FDA and submit a Biologics License Application in the first half of 2027.